From: Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment
Material | Templates and mechanisms | NIR-II PTAs and PCE | Tumor model | Biomedical applications | Reference |
---|---|---|---|---|---|
HPP | SiO2 | HPP; 45.1% | 4T1 tumor | PTT | [97] |
Ag2S Ve | self-assembly | Ag2S QDs; — | 4T1 tumor | NIR-II FLI and PTT | [98] |
AuHNRs-DTPP | Te nanorods | AuHNRs; — | H22 tumor | FLI and PTT/PDT | [99] |
AAM-Ce6 | galvanic replacement reaction | AAM-Ce6; 52.5% | HeLa tumor | PAI/FLI/MRI and PTT/PDT | [100] |
TAT-Pd@Au/Ce6/PAH/H-MnO2 | mSiO2 | TAT-Pd@Au; 56.9% | MCF-7 tumor | T1-weighted MRI and PTT/PDT | [101] |
AuHNRs-DOX | Se-doped Te nanorod | AuHNRs; 33% | SCC-7 tumor | PAI/CT imaging and PTT/chemotherapy | [102] |
NiP PHNPs-DOX | HCl solution etching | NiP PHNPs; 56.8% | U14 tumor | T1-weighted MRI/PAI and PTT/chemotherapy | [103] |
DSF@PEG-HCuS | nanoscale Kirkendall effect | DSF@PEG-HCuS; 23.8% | 4T1 tumor | PAI and PTT/chemotherapy | [104] |
PEG-Cu2Se HNCs | anion exchange method | Cu2Se HNCs; 50.89% | 4T1 tumor | PTT/CDT | [105] |
HSC-2 | nano-Beta zeolite | HSC-2; 41.41% | 4T1 tumor | NIR-II PAI/FLI and PTT/catalytic therapy | [106] |
HC-AB | beta zeolite | HC-AB; 25.45% | 4T1 tumor | NIR-II PAI and PTT/gas therapy | [107] |
DOX@H-Cu9S8/PEG | nanoscale Kirkendall effect | H-Cu9S8; 40.9% | CT26 tumor | NIR-II PAI and PTT/CDT/chemotherapy | [108] |
HMNC | Ostwald ripening process | HMNC; 36.3% | HeLa tumor | T2-weighted MRI and PTT/CDT/chemotherapy | [109] |
CPT-RHNS-PGEA/p53 | SiO2-RF-1 | RHNS-PGEA; 59.2% | 4T1 tumor | PAI and PTT/chemo/gene therapy | [110] |
PEG-CMS@GOx | nanoscale Kirkendall effect | CMS; 63.3% | U14 tumor | PTT/PDT/CDT/ST/ immunotherapy | [111] |